Literature DB >> 21931380

Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.

M Vivinus-Nébot1, R Dainese, R Anty, M C Saint-Paul, J L Nano, N Gonthier, S Marjoux, G Frin-Mathy, G Bernard, X Hébuterne, A Tran, V Theodorou, T Piche.   

Abstract

OBJECTIVES: Recent evidence suggests a role for increased colonic permeability and mucosal mast cell (MC) mediators on symptoms related to the irritable bowel syndrome (IBS). Whether allergic factors (AFs) are involved in the pathophysiology of IBS is unclear. We addressed the question of the possible influence of an allergic background on IBS symptoms.
METHODS: We assessed paracellular permeability, mucosal MCs counts, and spontaneous release of tryptase of colonic biopsy specimens in 34 IBS patients and 15 healthy subjects. The severity of IBS was assessed through self-reported questionnaires. All individuals were tested for the presence of AF, including self-perception of adverse reaction to food, personal and familial history of atopic disease, elevated total or specific immunoglobulin E against food/inhalant antigens, blood eosinophilia, and skin tests.
RESULTS: IBS patients had significant enhanced colonic permeability, higher number of MCs, and spontaneous release of tryptase than healthy subjects. The severity of IBS was significantly correlated with colonic permeability (r=0.48, P=0.004), MCs counts (r=0.36, P=0.03), and tryptase (r=0.48, P=0.01). In 13 IBS patients (38.2%) having at least three AFs, symptoms scores, colonic permeability, MCs counts, and tryptase release by colonic biopsies were significantly higher than in those with less than three AFs. IBS patients with at least three AFs were more prone to diarrhea or alternating symptoms. None AF was found to be predictive of IBS severity.
CONCLUSIONS: In IBS patients, the presence of an allergic background correlates with a more severe disease and diarrhea predominance, possibly by enhancing mucosal MC activation and paracellular permeability.

Entities:  

Mesh:

Year:  2011        PMID: 21931380     DOI: 10.1038/ajg.2011.315

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  44 in total

1.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

Review 2.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 3.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 4.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

5.  Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function.

Authors:  Stephanie A Peters; Shoko Edogawa; Wendy J Sundt; Roy B Dyer; Daniel A Dalenberg; Amelia Mazzone; Ravinder J Singh; Natalie Moses; Thomas C Smyrk; Christopher Weber; David R Linden; Wallace K MacNaughton; Jerrold R Turner; Michael Camilleri; David A Katzka; Gianrico Farrugia; Madhusudan Grover
Journal:  Am J Gastroenterol       Date:  2017-03-21       Impact factor: 10.864

6.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

7.  Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea.

Authors:  Michael Camilleri; Paula Carlson; Nelson Valentin; Andres Acosta; Jessica O'Neill; Deborah Eckert; Roy Dyer; Jie Na; Eric W Klee; Joseph A Murray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-21       Impact factor: 4.052

Review 8.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

Review 9.  The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.

Authors:  Paula Mosińska; Martin Storr; Jakub Fichna
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

Review 10.  Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.

Authors:  Kang Nyeong Lee; Oh Young Lee
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.